Despite intensive investigation, the genetic basis of chemotherapy-induced peripheral neurotoxicity (CIPN) remains elusive. In this critical update, Argyriou and colleagues highlight strategies for overcoming the methodological flaws of pharmacogenetic studies and the inadequacy of current tools for assessing CIPN. As yet, however, genetic profiling cannot identify patients at risk of CIPN or guide their management.
- Andreas A. Argyriou
- Jordi Bruna
- Guido Cavaletti
